Akebia Therapeutics (United States)

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · New England Journal of Medicine · 2020 · 924 citations · Full text

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Joseph L. Witztum, Daniel Gaudet, Steven D. Freedman et al. · New England Journal of Medicine · 2019 · 630 citations

Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides

Mark J. Graham, Richard Lee, Teresa Brandt et al. · New England Journal of Medicine · 2017 · 567 citations · Full text

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Daniel Gaudet, Ewa Karwatowska‐Prokopczuk, Seth J. Baum et al. · European Heart Journal · 2020 · 258 citations · Full text

Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD

Glenn M. Chertow, Pablo E. Pérgola, Youssef M.K. Farag et al. · New England Journal of Medicine · 2021 · 231 citations · Full text